| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02525991 | Agitation | Device: Staccato Delivery System Loxapine (ADASUVE) | Ferrer Internacional S.A. | Phase 4 | 2015-11-01 | 2015-08-17 |
| NCT02820519 | Neuropathic Pain | Drug: Loxapine | University of Witten/Herdecke | Phase 2 | 2016-06-01 | 2017-02-06 |
| NCT01854710 | Healthy Volunteers | Drug: ADASUVE 10 mg 2 doses 2 hours apart|Drug: Oral moxifloxacin 400 mg|Drug: Staccato Placebo 2 doses 2 hours apart|Drug: Placebo (for moxifloxacin) | Alexza Pharmaceuticals, Inc. | Phase 1 | 2013-05-01 | 2013-07-11 |
| NCT00890175 | Asthma | Drug: Inhaled loxapine @ 0 & 10 h|Drug: Inhaled placebo @ 2 & 10 hours | Alexza Pharmaceuticals, Inc. | Phase 1 | 2009-05-01 | 2017-03-13 |
| NCT00648778 | Healthy | Drug: Loxapine Succinate Capsules 25 mg|Drug: Loxitane Capsules 25 mg | Mylan Pharmaceuticals | Phase 1 | 2003-01-01 | 2008-03-31 |
| NCT02184767 | BiPolar | Drug: ADASUVE | Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries | Phase 1 | 2014-07-01 | 2016-02-26 |
| NCT00873769 | Smoking, Cigarette | Drug: Inhaled Loxapine 10 mg | Alexza Pharmaceuticals, Inc. | Phase 1 | 2009-04-01 | 2017-03-13 |
| NCT00889837 | Chronic Obstructive Pulmonary Disease | Drug: Inhaled Loxapine|Drug: Inhaled Placebo | Alexza Pharmaceuticals, Inc. | Phase 1 | 2009-06-01 | 2017-03-13 |
| NCT01877642 | Healthy Volunteers | Drug: ADASUVE 10 mg|Drug: Lorazepam 2 mg IM|Drug: Staccato Placebo|Drug: Placebo IM | Alexza Pharmaceuticals, Inc. | Phase 1 | 2013-06-01 | 2013-07-30 |
| NCT00290082 | Acute Agitated Patients | Drug: loxapine, midazolam|Biological: blood sample|Other: patient monitoring|Drug: Loxapine|Drug: Midazolam | University Hospital, Rouen | Phase 3 | 2005-12-01 | 2015-03-10 |
| NCT00628589 | Schizophrenic Patients With Acute Agitation | Drug: loxapine|Drug: loxapine|Drug: placebo | Alexza Pharmaceuticals, Inc. | Phase 3 | 2008-02-01 | 2008-06-10 |
| NCT00721955 | Bipolar I Disorder | Drug: loxapine|Drug: loxapine|Drug: placebo | Alexza Pharmaceuticals, Inc. | Phase 3 | 2008-07-01 | 2008-10-22 |
| NCT00555412 | Volunteers on Chronic, Stable Antipsychotic Regimens | Drug: A - 10 mg loxapine q 4 h x 3 (30 mg total)|Drug: B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)|Drug: C - 5 mg loxapine q 4 h x 3 (15 mg total)|Drug: D - inhaled placebo q 4 h x 3 | Alexza Pharmaceuticals, Inc.|Atlanta Center for Medical Research | Phase 1 | 2007-10-01 | 2017-03-13 |
| NCT01193816 | Restlessness | Drug: loxapine|Drug: Placebo | Assistance Publique - Hpitaux de Paris | Phase 4 | 2011-05-01 | 2014-07-17 |
| NCT00874237 | Healthy | Drug: 1 (Staccato Loxapine)|Drug: 2 (Moxifloxacin)|Drug: 3 (Placebo) | Alexza Pharmaceuticals, Inc. | Phase 1 | 2009-04-01 | 2009-06-18 |
| NCT00444028 | Schizophrenia | Drug: Loxapine thermal aerosol | Alexza Pharmaceuticals, Inc. | Phase 1 | 2005-10-01 | 2007-03-05 |
| NCT00489476 | Migraine | Drug: Loxapine Thermal Aerosol | Alexza Pharmaceuticals, Inc. | Phase 2 | 2007-06-01 | 2008-04-09 |
| NCT00122733 | Respiratory Insufficiency|Psychomotor Agitation | Drug: loxapine | Assistance Publique - Hpitaux de Paris | | 2005-12-01 | 2007-07-20 |
| NCT00369577 | Schizophrenia | Drug: Loxapine thermal aerosol | Alexza Pharmaceuticals, Inc. | Phase 2 | 2006-08-01 | 2007-01-18 |
| NCT00825500 | Migraine Headache | Drug: High dose|Drug: Low dose|Drug: Placebo | Alexza Pharmaceuticals, Inc. | Phase 2 | 2009-01-01 | 2017-01-30 |
| NCT00789360 | Healthy | Drug: Placebo -- Active|Drug: Active -- Placebo | Alexza Pharmaceuticals, Inc. | Phase 1 | 2008-11-01 | 2009-05-04 |
